Current Report

 



 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

 

CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (date of earliest event reported): March 27, 2019


APOLLO MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)


Delaware

001-37392

46-3837784

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)


1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801

(Address of principal executive offices) (zip code)


(626) 282-0288

(Registrant’s telephone number including area code)


N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company ¨

 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 



 



Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 27, 2019, Warren Hosseinion, M.D. resigned as Co-Chief Executive Officer and as a director of Apollo Medical Holdings, Inc. (the “Company”), effective March 28, 2019.  Dr. Hosseinion has advised the Company that his resignation is not due to any dispute or disagreement with the Company.  Thomas Lam, M.D., the Company’s other Co-Chief Executive Officer, will continue to serve as the sole Chief Executive Officer of the Company.  Dr. Lam has been the Company’s Co-Chief Executive Officer since December 2017.









 



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated:  April 1, 2019

APOLLO MEDICAL HOLDINGS, INC.

 

 

 

 

 

 

By:

/s/ Thomas S. Lam, M.D.

 

Name:

Thomas S. Lam, M.D.

 

Title:

Chief Executive Officer